JCM Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Millichap, J. J.
Right arrow Articles by Peterson, L. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Millichap, J. J.
Right arrow Articles by Peterson, L. R.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, July 2001, p. 2719-2721, Vol. 39, No. 7
0095-1137/01/$04.00+0   DOI: 10.1128/JCM.39.7.2719-2721.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Fluoroquinolone Resistance Is a Poor Surrogate Marker for Type II Topoisomerase Mutations in Clinical Isolates of Streptococcus pneumoniae

John J. Millichap,1,2 Ekaterina Pestova,1,2 Farida Siddiqui,1,2 Gary A. Noskin,1,2 and Lance R. Peterson1,2,*

Departments of Pathology and Medicine, Northwestern University Medical School,1 and Divisions of Microbiology and Infectious Diseases, Northwestern Memorial Hospital,2 Chicago, Illinois 60611

Received 18 December 2000/Returned for modification 7 March 2001/Accepted 20 April 2001

The association between fluoroquinolone susceptibility and DNA mutations coding for amino acid substitutions in the quinolone resistance-determining region was assessed with 44 clinical isolates of Streptococcus pneumoniae. Twenty-three strains bore at least one amino acid substitution. Only seven strains with mutations were suggested by diminished susceptibility to ciprofloxacin (MIC, >= 2 µg/ml).

* Corresponding author. Mailing address: Northwestern Prevention Epicenter, Department of Pathology, Galter Carriage House, Room 701, Northwestern Memorial Hospital, 251-East Huron, Chicago, IL 60611. Phone: (312) 926-2885. Fax: (312) 926-4139. E-mail: lancer{at}northwestern.edu.

Journal of Clinical Microbiology, July 2001, p. 2719-2721, Vol. 39, No. 7
0095-1137/01/$04.00+0   DOI: 10.1128/JCM.39.7.2719-2721.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS

Copyright © 2001 by the American Society for Microbiology. All rights reserved.